Clinical trials: Patients With Tumor
Multiple Myeloma
Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma
This clinical trial is a multicenter, cohort, with one arm to study the SLP to 18 months of Velcadito scheme (velcade 1.0 mg / m2 administered over two days with melphalan and prednisone) in patients with MM diagnosis again…
- Trial name
- Velcadito (NCT02773550)
- Testing
- Bortezomib, Melphalan, Prednisone
- Where
- Spain
- Volunteers
- 24 people
- Sponsor
- Basque Health Service
Advanced Solid Tumor
AMT-116 in Patients With Advanced Solid Tumors
This first-in-human study will evaluate the Maximum Tolerated Dose (MTD) / the Recommended Phase 2 Dose (RP2D), safety, tolerability, anti-tumor activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-116, in…
- Trial name
- NCT05725291
- Testing
- AMT-116
- Where
- 10 sites in United States, American Samoa and 1 more
- Volunteers
- 80 people
- Sponsor
- Multitude Therapeutics Inc.
Lymphoma
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392990
- Testing
- Regimen A, Regimen B
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Northwestern University
Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
This phase I trial is studying the side effects and best dose of sorafenib and bortezomib in treating patients with advanced cancer.
- Conditions
- Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia
- Trial name
- NCT00303797
- Testing
- 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
- Trial name
- NCT01170897
- Testing
- PEGPH20
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- Halozyme Therapeutics
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
This phase I trial studies the side effects and how well CART-BCMA/CS1 works in treating patients with multiple myeloma (MM) that has come back (relapsed) or that does not respond to treatment (refractory).
- Trial name
- NCT05950113
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
NonHodgkin Lymphoma, Lymphoproliferative Disorders
Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)
Subjects have a type of a lymph node cancer called Non-Hodgkin's Lymphoma (NHL) or lymphoproliferative disease (LPD), which affects their immunity, blood production, and can involve multiple other organs in the body.
- Conditions
- NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD
- Trial name
- PREVALE (NCT02973113)
- Testing
- EBVST Cells, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Baylor College of Medicine
Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Neuroendocrine Tumor (NET)
Nutrition Intervention for Pancreatic Cancer
Patients with pancreatic cancer (pancreatic ductal adenocarcinoma (PDAC) and pancreatic neuroendocrine tumor (NET)) commonly experience fat malabsorption due to exocrine pancreatic insufficiency (EPI) and leads to…
- Trial name
- NCT07554560
- Testing
- Structured Lipid Medical Food
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Hospital of Philadelphia
Glioma, Glioblastoma
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
It was previously shown that [18F]Fluorodopa (FDOPA) PET imaging results in intended management changes in 41% of brain tumor patients.
- Conditions
- Glioma, Glioblastoma, Glioblastoma Multiforme
- Trial name
- NCT02176720
- Testing
- FDOPA PET
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- The Methodist Hospital Research Institute
Lung Neoplasms
Early Lung Cancer Detection in Patients With Sputum Cytology and Autofluorescence Bronchoscopy in People at High Risk of Lung Cancer
Lung cancer is the commonest malignant disease with a 5-year survival of 14%. In Hong Kong, it accounts for about 30% of all cancer death.
- Trial name
- NCT00563420
- Testing
- Bronchoscopy
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Hospital Authority, Hong Kong
Ovarian Cancer, Solid Tumor
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
- Trial name
- NCT06234423
- Testing
- CUSP06
- Where
- 15 sites in United States, Australia
- Volunteers
- 263 people
- Sponsor
- OnCusp Therapeutics, Inc.
Non Small Cell Lung Cancer
Safety of Everolimus and Pemetrexed in Lung Cancer Patients
This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.
- Trial name
- NCT00434174
- Testing
- Everolimus, Pemetrexed
- Where
- 5 sites in Australia, Belgium and 1 more
- Volunteers
- 48 people
- Sponsor
- Novartis Pharmaceuticals
Small Cell Lung Cancer
SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This study is a single arm, multi-center, open label phase Ib/II study of SC0245 and Irinotecan combination therapy in subjects with extensive-stage small cell lung cancer (ES-SCLC) as a second therapy.
- Trial name
- NCT05731518
- Testing
- SC0245, Irinotecan
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Colorectal Cancer
A Study of PRO95780 in Combination With Cetuximab and Irinotecan Chemotherapy or the FOLFIRI Regimen With Bevacizumab in Patients With Previously Treated Metastatic Colorectal Cancer (APM4187g)
This is a Phase Ib, open-label, multicenter, dose-escalation study designed to assess if PRO95780 in combination with two different irinotecan-containing regimens is safe and tolerable in patients with metastatic colorectal…
- Trial name
- NCT00497497
- Testing
- bevacizumab, cetuximab, FOLFIRI regimen
- Volunteers
- 20 people
- Sponsor
- Genentech, Inc.
Non Small Cell Lung Cancer
Trial of Poor Performance Status Patients (ToPPS)
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
- Trial name
- ToPPS (NCT00892710)
- Testing
- Pemetrexed, Bevacizumab, Carboplatin
- Where
- 27 sites in United States
- Volunteers
- 172 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer (Advanced/Metastatic)
Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)
This is a Phase II, single-arm, Bayesian adaptive trial. The study employs a two-stage design with an interim analysis after 30 evaluable patients and a maximum enrolment of 60 patients.
- Trial name
- HERBRAIN (NCT07905313)
- Testing
- SRS/fSRT+T-Dxd
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Mesothelioma, Epithelioid Hemangioendothelioma(EHE)
A Study of BGC515 Capsules in Subjects With Advanced Solid Tumors
The goal of this open-label, dose escalation and dose expansion Phase I clinical trial is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of BGC515 administered once daily in 3 weeks cycles in…
- Conditions
- Mesothelioma, Epithelioid Hemangioendothelioma(EHE), Solid Tumor
- Trial name
- NCT06452160
- Testing
- BGC515
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- BridGene Biosciences Inc.
HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma
This is a multi-center study in patients with un-resectable Recurrent or Metastatic HPV16-positive oropharyngeal Head and Neck Squamous Cell Carcinoma (HNSCC).
- Trial name
- NCT06016920
- Testing
- VB10.16, Pembrolizumab
- Where
- 12 sites in France, Germany and 5 more
- Volunteers
- 110 people
- Sponsor
- Nykode Therapeutics ASA
Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the…
- Conditions
- Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8, Stage IIB Rectal Cancer AJCC v8
- Trial name
- NCT05081024
- Testing
- Biopsy, Biospecimen Collection, Electronic Health Record Review
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- OHSU Knight Cancer Institute
Non-Small Cell Lung Cancer
CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer
Lung cancer is the most common cancer worldwide, non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancer cases, which is the leading cause of cancer mortality, and adenocarcinoma is the most prevalent subtype.
- Trial name
- NCT01871480
- Testing
- Group A:cytokine-induced killer cell +gefitinib, Group B:Gefitinib
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Kunming Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.